In late 2021, amid a broader pandemic-fuelled surge in remote healthcare and virtual care solutions, electronics retailer Best Buy sought to expand its healthcare footprint under its "Best Buy Health" banner. The cornerstone of this healthcare expansion was the acquisition of Current Health, an at-home care and remote patient monitoring platform, for approximately $400 Million. However, by June 2025, the retail giant shifted its strategy, divesting Current Health back to its

The global healthcare navigation platform market is undergoing a profound structural evolution, driven by the escalating complexity of health insurance systems, rising catastrophic claim costs, and a strategic shift toward value-based, outcome-driven care. Market volume projections indicate rapid expansion, with the global healthcare navigation sector growing from $13.35 Billion in 2025 to $14.92 Billion in 2026 at an annual rate of 11.7%.

European HealthTech experienced a highly pivotal week, marked by major pan-European regulatory shifts, massive infrastructure contracts, and the largest digital health gathering of the year in Barcelona. The industry is moving away from speculative "wellness" technology and entering a phase of strict clinical validation and data compliance. The European MedTech sector saw massive movement this week, dominated by a coordinated legislative overhaul from the European Commission

In the United Kingdom’s National Health Service (NHS), the Trust Integration Engine (TIE) represents a critical and highly visible component of the clinical information technology estate. Acting as the central middleware "conductor" for an individual hospital Trust’s software applications, the TIE translates, secures and routes real-time clinical messages across a localised, highly fragmented digital landscape. However, when analysing the digital health ecosystems of the Unit

The deployment of virtual wards within the British National Health Service (NHS) has transitioned from a localised pandemic response into a central pillar of national healthcare architecture. This shift is codified in the government’s ten-year health plan for England, "Fit for the Future," which establishes a clear clinical hierarchy: care must occur locally, digitally by default, in a patient’s home if possible, in a neighbourhood health centre when needed and in a physical

The transition of the consumer biometrics and wearable informatics landscape has reached a critical inflection point. On May 19th, 2026, Google initiated a mandatory software deployment that formally rebranded and structurally consolidated the legacy Fitbit application into Google Health 5.0. This update, which achieved full global availability on May 26th, 2026, represents a fundamental re-engineering of Google’s health and fitness architecture. Rather than treating the acqu

This has been a big week for European HealthTech, largely anchored by the major HIMSS26 Europe conference in Copenhagen alongside sweeping regulatory actions from the European Commission. The European MedTech sector is experiencing its most critical regulatory and commercial shake-up in years. A wave of structural overhauls from Brussels and London is colliding with a mandatory compliance deadline next week, completely shifting the operating landscape for device manufacturers

The consolidation of GHO Capital and CBC Group represents a notable evolution in the alternative asset management landscape, characterised by the rise of "mega-specialist" managers. This transaction also highlights the strategic role of technology and artificial intelligence (AI) as critical tools for value creation and operational efficiency in the life sciences sector. As noted by the executive leadership, the integration of AI applications into drug discovery, diagnostic i

Healthcare technology stands out as one of the strongest themes in the 2026 CNBC Disruptor 50, but it is now framed almost entirely through an AI and data infrastructure lens rather than classic digital health point solutions.

Alcidion Group (ASX: ALC) signed an Asset Sale Agreement on 16th May 2026 to acquire three Kyra patient flow products from Telstra Health: Kyra Patient Flow Manager, Kyra Queue Manager, and Kyra IQ. The upfront cash consideration is $3.0 Million, funded from Alcidion's existing cash reserves of $15.1 Million (no debt as of 31st March 2026), with a further earn-out of up to $1.0 Million tied to recurring revenue thresholds over 12 months post-completion. Completion is expected

On May 19th, 2026, ResMed (NYSE: RMD, ASX: RMD), a prominent global health technology company specialising in sleep, breathing and home-delivered respiratory care and ŌURA, the manufacturer of the leading smart ring, announced a strategic partnership. This cross-industry collaboration represents a structured initiative to connect daily consumer wellness tracking with professional medical diagnostic and treatment networks. By linking Oura's passive biometric telemetry with Res

They are called Founder Bankers: former entrepreneurs and clinicians who built, scaled and exited their own healthcare technology ventures before transitioning into the advisory role. The model fuses deep operational pedigree with sophisticated investment banking methodology, offering what traditional finance cannot easily replicate, fluency in the lived experience of company-building, clinical pathway navigation and the psychological complexity of founder exit events.​​

The healthcare sector is undergoing a profound structural evolution as artificial intelligence (AI) transitions from an assistive, reactive tool into an autonomous execution layer. According to financial assessments, global AI expenditure is projected to rise from $1.76 Trillion in 2025 to $2.52 Trillion in 2026, before reaching $3.34 Trillion in 2027. A significant concentration of venture capital is driving this transformation; AI firms raised approximately $242 Billion in

The European healthtech and medtech sectors have entered a phase of disciplined maturity, transitioning away from the venture subsidised experimentation of the early 2020s toward an era characterised by industrialisation and regulatory Darwinism. In the current market environment of 2025 and 2026, the criteria for a successful Series A funding round have shifted fundamentally. Investors no longer prioritise raw user acquisition or speculative growth; instead, they demand a ri

The European healthcare technology and medical technology landscape has entered a profound inflection point as it moves through 2025 and into 2026. This period is increasingly defined by a transition from the speculative fragmentation and "growth-at-all-costs" mindset of the early 2020s to a disciplined, professionalised era termed industrial maturity. For companies preparing to raise a Series C funding round in this environment, the requirements have shifted from simple user